Compare ALVO & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALVO | JFR |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Luxembourg | United States |
| Employees | 1460 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | N/A |
| Metric | ALVO | JFR |
|---|---|---|
| Price | $3.54 | $7.45 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 366.2K | ★ 732.1K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.31% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.28 | N/A |
| Revenue Next Year | $18.63 | N/A |
| P/E Ratio | $18.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.03 | $7.16 |
| 52 Week High | $11.85 | $8.59 |
| Indicator | ALVO | JFR |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 47.59 |
| Support Level | $3.03 | $7.23 |
| Resistance Level | $3.93 | $7.61 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 51.04 | 9.76 |
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.